GeoVax Labs, Inc. (GOVXW)

US — Healthcare Sector
Peers: ARTLW  ENTXW  ATNFW  VRMEW  BCDAW 

Automate Your Wheel Strategy on GOVXW

With Tiblio's Option Bot, you can configure your own wheel strategy including GOVXW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol GOVXW
  • Rev/Share 0.4677
  • Book/Share 0.6607
  • PB 1.5742
  • Debt/Equity 0.0
  • CurrentRatio 3.6154
  • ROIC -3.1231

 

  • MktCap 15801344.0
  • FreeCF/Share -2.0894
  • PFCF -0.6326
  • PE -0.5075
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -5.1198

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About GeoVax Labs, Inc. (GOVXW)

  • IPO Date
  • Website https://www.geovax.com
  • Industry Biotechnology
  • CEO Mr. David Alan Dodd
  • Employees 17

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is also developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; GEO-EM01 for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. GeoVax Labs, Inc. has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.